Angiotensin II and Vasopressin for Vasodilatory Shock: A Critical Appraisal of Catecholamine-Sparing Strategies. (June 2021)

• Record Type: Journal Article
• Authors: Heavner, Mojdeh S.; McCurdy, Michael T.; Mazzeffi, Michael A.; Galvagno, Samuel M.; Tanaka, Kenichi A.; Chow, Jonathan H.
• Is Part Of: Journal of intensive care medicine. Volume 36:Number 6(2021)
• Page Start: 635
• Page End: 645
• Publication Date: 2021-06
• Subjects: angiotensin II -- vasopressin -- vasodilatory shock -- catecholamines -- distributive shock -- septic shock; Critical care medicine -- Periodicals; Critical Care -- Periodicals; Soins intensifs -- Périodiques; Soins intensifs; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.02805
• DOI: 10.1177/0885066620911601
• Languages: English
• ISSNs: 0885-0666

Abstract

Vasodilatory shock is a serious medical condition that increases the morbidity and mortality of perioperative and critically ill patients. Norepinephrine is an established first-line therapy for this condition, but at high doses, it may lead to diminishing returns. Oftentimes, secondary noncatecholamine agents are required in those whose hypotension persists. Angiotensin II and vasopressin are both noncatecholamine agents available for the treatment of hypotension in vasodilatory shock. They have distinct modes of action and unique pharmacologic properties when compared to norepinephrine. Angiotensin II and vasopressin have shown promise in certain subsets of the population, such as those with acute kidney injury, high Acute Physiology and Chronic Health Evaluation II scores, or those receiving cardiac surgery. Any benefit from these drugs must be weighed against the risks, as overall mortality has not been shown to decrease mortality in the general population. The aims of this narrative review are to provide insight into the historical use of noncatecholamine vasopressors and to compare and contrast their unique modes of action, physiologic rationale for administration, efficacy, and safety profiles.